Antimicrobial materials for endotracheal tubes: A review on the last two decades of technological progress
Source abstract
Abstract
Ventilator-associated pneumonia (VAP) is an unresolved problem in nosocomial settings, remaining consistently associated with a lack of treatment, high mortality, and prolonged hospital stay. The endotracheal tube (ETT) is the major culprit for VAP development owing to its early surface microbial colonization and biofilm formation by multiple pathogens, both critical events for VAP pathogenesis and relapses. To combat this matter, gradual research on antimicrobial ETT surface coating/modification approaches has been made. This review provides an overview of the relevance and implications of the ETT bioburden for VAP pathogenesis and how technological research on antimicrobial materials for ETTs has evolved. Firstly, certain main VAP attributes (definition/categorization; outcomes; economic impact) were outlined, highlighting the issues in defining/diagnosing VAP that often difficult VAP early- and late-onset differentiation, and that generate misinterpretations in VAP surveillance and discrepant outcomes. The central role of the ETT microbial colonization and subsequent biofilm formation as fundamental contributors to VAP pathogenesis was then underscored, in parallel with the uncovering of the polymicrobial ecosystem of VAP-related infections. Secondly, the latest technological developments (reported since 2002) on materials able to endow the ETT surface with active antimicrobial and/or passive antifouling properties were annotated, being further subject to critical scrutiny concerning their potentialities and/or constraints in reducing ETT bioburden and the risk of VAP while retaining/improving the safety of use. Taking those gaps/challenges into consideration, we discussed potential avenues that may assist upcoming advances in the field to tackle VAP rampant rates and improve patient care. STATEMENT OF SIGNIFICANCE: The use of the endotracheal tube (ETT) in patients requiring mechanical ventilation is associated with the development of ventilator-associated pneumonia (VAP). Its rapid surface colonization and biofilm formation are critical events for VAP pathogenesis and relapses. This review provides a comprehensive overview on the relevance/implications of the ETT biofilm in VAP, and on how research on antimicrobial ETT surface coating/modification technology has evolved over the last two decades. Despite significant technological advances, the limited number of gathered reports (46), highlights difficulty in overcoming certain hurdles associated with VAP (e.g., persistent colonization/biofilm formation; mechanical ventilation duration; hospital length of stay; VAP occurrence), which makes this an evolving, complex, and challenging matter. Challenges and opportunities in the field are discussed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nosocomial Infections in ICU · Inhalation and Respiratory Drug Delivery · Legionella and Acanthamoeba research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Reduction of endotracheal tube biofilms using antimicrobial photodynamic therapy10.1002/lsm.21103 ↗
2. Antimicrobial polymer modifications to reduce microbial bioburden on endotracheal tubes and ventilator-associated pneumonia10.1016/j.actbio.2019.04.042 ↗
3. R.D. Scott, The Direct Medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention, Division of Healthcare Quality Promotion National Center for Preparedness, Detection, and Control of Infectious Diseases Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention, Atlanta 2009. https://stacks.cdc.gov/view/cdc/11550.
4. How common are indwelling devices in hospitalized adults? A contemporary point prevalence study in a tertiary care hospital10.1016/j.ajic.2020.06.205 ↗
5. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society10.1093/cid/ciw353 ↗
6. Ventilator-associated pneumonia10.1164/ajrccm.165.7.2105078 ↗
7. American Thoracic, Society, Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am. J. Respir. Crit. Care Med. 171 (2005) 388–416.10.1164/rccm.200405-644ST ↗
8. Diagnosis of ventilator-associated respiratory infections (VARI): microbiologic clues for tracheobronchitis (VAT) and pneumonia (VAP)10.1016/j.ccm.2011.06.001 ↗
9. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury10.1378/chest.80.3.254 ↗
10. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies10.4187/respcare.02173 ↗
11. Comparison of microbiological profile of pathogens isolated from early-onset and late-onset ventilator-associated pneumonia in a tertiary care center10.4103/1119-0388.172073 ↗
12. Early- and late-onset pneumonia: is this still a useful classification?10.1128/AAC.01070-08 ↗
13. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia10.1183/13993003.00582-2017 ↗
14. Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia10.1183/23120541.00028-2018 ↗
15. Microorganisms and clinical outcomes of early- and late-onset ventilator-associated pneumonia at Srinagarind Hospital, a tertiary center in Northeastern Thailand10.1186/s12890-021-01415-8 ↗
16. Ventilator-associated pneumonia (VAP) - early and late-onset differences10.1183/13993003/erj.42.Suppl_57.P2457 ↗
17. Differences in early- and late-onset ventilator-associated pneumonia between surgical and trauma patients in a combined surgical or trauma intensive care unit
18. The impact of onset time on the isolated pathogens and outcomes in ventilator-associated pneumonia10.1016/j.jiph.2015.09.002 ↗
19. The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with the occurrence of pneumonia10.1136/thoraxjnl-2016-209158 ↗
20. Developing a new, National approach to surveillance for ventilator-associated events10.4037/ajcc2013893 ↗
21. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting10.1016/j.ajic.2008.03.002 ↗
22. Ventilator-associated events: what they are and what they are not10.4187/respcare.07059 ↗
23. The epidemiology and clinical outcomes of ventilator-associated events among 20,769 mechanically ventilated patients at intensive care units: an observational study10.1186/s13054-021-03484-x ↗
24. Impact of diagnostic criteria on the incidence of ventilator-associated pneumonia10.1378/chest.14-0610 ↗
25. Epidemiology and outcome of ventilator-associated pneumonia in a heterogeneous ICU population in Qatar10.1155/2016/8231787 ↗
26. International nosocomial infection control consortium (INICC) report, data summary for 2003-2008, issued June 200910.1016/j.ajic.2009.12.004 ↗
27. National healthcare safety network report, data summary for 2011, device-associated module10.1016/j.ajic.2013.01.002 ↗
28. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study10.1007/s10096-016-2703-z ↗
29. European Centre for Disease Prevention and Control, Annual epidemiological report 2011, Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC 2011. https://www.ecdc.europa.eu/en/publications-data/annual-epidemiological-report-2011-2009-data (accessed October 16, 2022).
30. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in adult intensive care units from 14 developing countries of four continents: findings of the international nosocomial infection control consortium10.1097/CCM.0b013e3182657916 ↗
31. Ventilator-associated pneumonia and bloodstream infections in intensive care unit cancer patients: a retrospective 12-year study on 3388 prospectively monitored patients
32. Ventilator-associated pneumonia is more common and of less consequence in trauma patients compared with other critically ill patients
33. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients10.1164/ajrccm/142.3.523 ↗
34. Determinants of the length of mechanical ventilation in patients with COPD in the intensive care unit10.1159/000083402 ↗
35. Impact of ventilator-associated pneumonia on outcome in patients with COPD10.1378/chest.128.3.1650 ↗
36. Incidence, risk factors, and outcome of ventilator-associated pneumonia10.1016/j.jcrc.2005.08.005 ↗
37. The results of a 6-year epidemiologic surveillance for ventilator-associated pneumonia at a tertiary care intensive care unit in Saudi Arabia10.1016/j.ajic.2011.10.004 ↗
38. Ventilator-associated pneumonia in adults: a narrative review10.1007/s00134-020-05980-0 ↗
39. Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies10.21037/atm.2017.09.16 ↗
40. Preventing ventilator-associated infections10.1016/j.ccm.2016.07.008 ↗
41. Healthcare-associated infections (HAI) perspectives10.1016/j.jiph.2014.04.003 ↗
42. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system10.1001/jamainternmed.2013.9763 ↗
43. Economic impact of ventilator-associated pneumonia in a large matched cohort10.1086/664049 ↗
44. Number needed to treat and cost-effectiveness in the prevention of ventilator-associated pneumonia10.1186/cc11346 ↗
45. Extra length of stay and costs because of health care–associated infections at a German university hospital10.1016/j.ajic.2015.09.005 ↗
46. Estimating extra length of stay due to healthcare-associated infections before and after implementation of a hospital-wide infection control program10.1371/journal.pone.0217159 ↗
47. Endotracheal tubes: old and new10.4187/respcare.02868 ↗
48. Risk factors of ventilator-associated pneumonia in critically III patients10.3389/fphar.2019.00482 ↗
49. Ventilator-associated pneumonia: evolving definitions and preventive strategies10.4187/respcare.02380 ↗
50. Risk and prognostic factors of ventilator-associated pneumonia in trauma patients10.1097/01.CCM.0000206471.44161.A0 ↗
51. Respiratory therapy device modifications to prevent ventilator-associated pneumonia10.1097/QCO.0b013e32835d3349 ↗
52. Biofilm formation on three different endotracheal tubes: a prospective clinical trial10.1186/s13054-020-03092-1 ↗
53. Endotracheal tube biofilm and its impact on the pathogenesis of ventilator-associated pneumonia10.2478/jccm-2018-0011 ↗
54. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept10.1186/cc11357 ↗
55. Molecular analysis of microbial communities in endotracheal tube biofilms10.1371/journal.pone.0014759 ↗
56. Cilia and mucociliary clearance10.1101/cshperspect.a028241 ↗
57. Airway clearance therapy in acute paediatric respiratory illness: a state-of-the-art review10.4102/sajp.v75i1.1295 ↗
58. Ventilator-associated pneumoniarisk factors and prevention10.4037/ccn2007.27.4.32 ↗
59. Tracheal tube biofilm as a source of bacterial colonization of the lung10.1128/jcm.27.9.2014-2018.1989 ↗
60. Tracheal tube obstruction in mechanically ventilated patients assessed by high-resolution computed tomography10.1097/ALN.0000000000000455 ↗
61. Modifying endotracheal tubes to prevent ventilator-associated pneumonia10.1097/QCO.0b013e328343b733 ↗
62. Description and microbiology of endotracheal tube biofilm in mechanically ventilated subjects10.4187/respcare.02722 ↗
63. Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube10.1097/ALN.0b013e31819868e0 ↗
64. Prolonged inhibitory effects against planktonic growth, adherence, and biofilm formation of pathogens causing ventilator-associated pneumonia using a novel polyamide/silver nanoparticle composite-coated endotracheal tube10.1080/08927014.2020.1759041 ↗
65. The biofilm matrix10.1038/nrmicro2415 ↗
66. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics10.1128/MMBR.00013-14 ↗
67. Antibiotics versus biofilm: an emerging battleground in microbial communities10.1186/s13756-019-0533-3 ↗
68. Nosocomial pathogen biofilms on biomaterials: Different growth medium conditions and components of biofilms produced in vitro10.1016/j.jmii.2020.07.002 ↗
69. Efficient surface modification of biomaterial to prevent biofilm formation and the attachment of microorganisms10.1007/s00253-012-4144-7 ↗
70. Biofilms: an emergent form of bacterial life10.1038/nrmicro.2016.94 ↗
71. Molecular analysis of biofilms on the surface of neonatal endotracheal tubes based on 16S rRNA PCR-DGGE and species-specific PCR
72. New approaches for the prevention of airway infection in ventilated patients. Lessons learned from laboratory animal studies at the National Institutes of Health
73. Microbial composition and antibiotic resistance of biofilms recovered from endotracheal tubes of mechanically ventilated patients10.1007/978-3-319-11038-7_9 ↗
74. Prevention of ventilator-Associated and early postoperative pneumonia through tapered endotracheal tube cuffs: a systematic review and meta-analysis of randomized controlled trials10.1097/CCM.0000000000002889 ↗
75. Randomized intubation with polyurethane or conical cuffs to prevent pneumonia in ventilated patients10.1164/rccm.201408-1398OC ↗
76. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: a systematic review and network meta-analysis10.1136/bmj.g2197 ↗
77. Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome10.1016/j.ebiom.2020.102995 ↗
78. Assessment of microbial diversity in biofilms recovered from endotracheal tubes using culture-dependent and independent approaches10.1371/journal.pone.0038401 ↗
79. A novel antibacterial and antifouling nanocomposite coated endotracheal tube to prevent ventilator-associated pneumonia
80. Colonisation of the upper respiratory tract with Gram-negative bacilli after operation, endotracheal intubation and prophylactic antibiotic therapy10.1111/j.1365-2044.1967.tb02722.x ↗
81. Nosocomial pulmonary infection: Possible etiologic significance of bacterial adhesion to endotracheal tubes10.1097/00003246-198604000-00001 ↗
82. Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?10.1080/17476348.2019.1632195 ↗
83. Drug prevention and control of ventilator-associated pneumonia10.3389/fphar.2019.00298 ↗
84. Aspiration pneumonia10.1056/NEJMra1714562 ↗
85. Implications of endotracheal tube biofilm for ventilator-associated pneumonia10.1007/s001340051014 ↗
86. Mechanisms of biofilm resistance to antimicrobial agents10.1016/S0966-842X(00)01913-2 ↗
87. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material10.1128/AAC.27.4.619 ↗
88. Microbial communities in the respiratory tract of patients with interstitial lung disease10.1136/thoraxjnl-2012-202917 ↗
89. Disordered microbial communities in asthmatic airways10.1371/journal.pone.0008578 ↗
90. Composition and dynamics of the respiratory tract microbiome in intubated patients10.1186/s40168-016-0151-8 ↗
91. Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients10.1016/j.jgar.2016.12.016 ↗
92. The microbiology of ventilator-associated pneumonia10.4187/respcare.05500742 ↗
93. Clinical characteristics and outcomes of neonates with polymicrobial ventilator-associated pneumonia in the intensive care unit10.1186/s12879-021-06673-9 ↗
94. Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention10.2217/fmb-2018-0108 ↗
95. Polymicrobial ventilator-associated pneumonia: fighting in vitro Candida albicans-Pseudomonas aeruginosa biofilms with antifungal-antibacterial combination therapy
96. Strategies to prevent ventilator-associated pneumonia in neonates10.1016/j.clp.2010.05.003 ↗
97. Ventilator-associated pneumonia in neonatal patients: an update10.1159/000355539 ↗
98. Endotracheal tube biofilm inoculation of oral flora and subsequent colonization of opportunistic pathogens10.1016/j.ijmm.2010.02.005 ↗
99. The endotracheal tube microbiome associated with Pseudomonas aeruginosa or Staphylococcus epidermidis10.1038/srep36507 ↗
100. Signal-mediated interactions between Pseudomonas aeruginosa and Candida albicans10.1099/jmm.0.47705-0 ↗